Boehringer’s Next Gen Protease Inhibitor Potent In Tough-to-Treat Hep C Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II data presented at the American Association for the Study of Liver Disease meeting on BI 201335 support efficacy in hard to treat genetic subtypes and with shorter treatment periods.